Table 5 Other hydroxamate and anilide HDACi trials reported in 2009 and 2010
From: Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Combination therapy | Type of cancer | Phase | N | Outcome (most relevant findings) | Literature |
|---|---|---|---|---|---|
Givinostat | Relapsed/progressive multiple myeloma | II | n = 19 | 5SD; MTD 100 mg twice daily | Galli et al. (2010) |
Mocetinostat | Advanced chronic lymphocytic leukemia | II | 21 | No response | Blum et al. (2009) |
Entinostat+5-Azacytidine | Myeloid Malignancies | I | 38 | 3 CR, 4 PR, 7 HI | Fandy et al. (2009) |